Philips and IBA sign an
exclusive alliance to enhance access to proton therapy in India
Royal
Philips (NYSE: PHG, AEX: PHIA), a leader in image-guided therapiesand IBA(Ion
Beam Applications S.A., EURONEXT), the world’s leading provider of proton
therapy solutions for the treatment of cancer, today announced the signing of
an exclusive agreement to enhance access to proton therapy in India.
The alliance combines Philips’
expertisein clinical informatics and innovative imaging techniques for therapy
planning and guidance andIBA’s strengths in proton therapy.
Leveraging high quality imaging and
proton therapy offers the potential to increase confidence in the diagnosis and
treatment of cancer, reduce short- and long-term side-effects and potentially
enhance the quality of life of the patient before, during and after treatment.Advanced MRI, PET and CT
imaging technologies will help physicians better target proton beam delivery to
destroy cancer cells whilst avoiding healthy tissue.
This agreement builds upon
thecollaboration between Philips India and IBA, which started in 2013, to build
the Apollo Proton Therapy Center, the first proton therapy center in India.
Mr. Sameer
Garde, President, Philips Healthcare said: “We are very pleased to announce
that Philips India and IBA are introducing the best-in-class proton beam
therapy for cancer patients in India. We are confident that the future launch
of the first proton therapy center in Apollo Hospitals, Chennai, will mark the
beginning of a new phase in cancer treatment in the country and also the
subcontinent”.
Mr. Olivier
Legrain, Chief Executive Officer, IBA, added: “We are privileged that Philips
Indiais supporting us in bringingcutting edge proton beam therapy to India. We
are certain that this initiative will be a significant step in improving the
quality of cancer treatment in the country.With this collaboration, IBA further
strengthens its world leading position in proton therapy and stays at the
forefront of delivering the latest in innovative cancer therapy to the Asia
region.Globally, IBA has now sold 33 proton therapy centers, more than all
other providers combined.”
Proton therapy is an important
addition to cancer treatment in India given that the incidence of cancer is
70-90 per 100,000 people with children comprising nearly 5 per cent of these
patients. Proton therapy is considered to be one of the most advanced treatments
available in the fight against cancer. With the precision that proton therapy
offers, it is possible to target the tumor more effectively while limiting the
side effects of the treatment. Protons deposit the majority of their energy
within a precisely controlled zone, directly in the tumor while limiting the
impact on healthy tissues surrounding the tumor.
 |
| Sameer Garde, President, Philips Healthcare with Olivier Legrain, CEO, IBA |
Proton therapy is particularly appropriate
for the treatment of eye and brain cancers, tumors close to the brain stem and
spinal cord as well as prostate, liver, lung cancers. Proton therapy is also
extremely well-suited for the treatment of pediatric cancers.
The exclusive Philips-IBA agreement
for India follows the framework agreement that Philips and IBA signed in
September of last year. The framework agreement comprisesresearch and
development, marketing and sales of imaging and therapy solutions in oncology.
The collaboration also enables both organizations to mutually leverage
technologies and solutions:
IBA benefits from Philips diagnostic imaging
products offered to oncology care centers, while Philips will leverage IBA
proton therapy solutions within its offering for customers in select markets
around the world. As part of the framework agreement, Philips and IBA have
already signed multiple country-specific collaboration agreements, each
optimized for the local market needs.
For a video on proton therapy, please
visit this link:
For
further information, please contact:
Sumathi
Rao
Corporate Communications
Philips India Limited
(T): +91- 9845210362
Saumya Bhushan
(T): +91- 9840003993
IBA
Jean-Marc Bothy
Chief Financial Officer
Tel: +32 10 47 58 90
Thomas Ralet
Vice-President Corporate Communication
+32 10 47 58 90
For media and investor enquiries:
Consilium Strategic Communications
Amber Bielecka, Matthew Neal, Jessica Hodgson
and Ivar Milligan
+44 (0) 203 709 5700
About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA)
is a diversified health and well-being company, focused on improving people's
lives through meaningful innovation in the areas of Healthcare, Consumer
Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014
sales of EUR 21.4 billion and employs approximately 108,000 employees with
sales and services in more than 100 countries. The company is a leader in
cardiac care, acute care and home healthcare, energy efficient lighting
solutions and new lighting applications, as well as male shaving and grooming
and oral healthcare. News from Philips is located at www.philips.com/newscenter.
About IBA:
IBA (Ion Beam Applications S.A.) is a
global medical technology company focused on bringing integrated and innovative
solutions for the diagnosis and treatment of cancer. The Company is the
worldwide technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today.
IBA’s proton therapy solutions are
flexible and adaptable, allowing customers to choose from universal full scale
proton therapy centers as well as compact, single room systems. In addition,
IBA also has a radiation dosimetry business and develops particle accelerators
for the medical world and industry.
Headquartered in Belgium and
employing about 1100 people worldwide, IBA has installed systems across the
world, from Europe and the US and to the emerging markets. IBA is listed on the
pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg
IBAB.BB) and more information can be found at: www.iba-worldwide.com
No comments:
Post a Comment